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Résumé 
Nous avons effectué une étude de cohorte examinant la survie de tous les patients 
qui ont présenté une sepsis sévère ou un choc septique aux soins intensifs de 
médecine et de chirurgie du CHUV durant une période de 3 ans. 
Introduction: La sepsis sévère et le choc septique constituent la deuxième cause 
de mortalité dans les unités de soins intensifs non coronaires. La survie à long 
terme est mal connue. Nous avons comparé la survie à 28 jours de notre collectif 
avec les données de la littérature, examiné la survie à long terme des patients ayant 
survécus plus de 28 jours et identifié des paramètres prédictifs de la survie. 
Matériel et méthode : Nous avons classifié les patients ayant présenté un 
épisode septique rétrospectivement en sepsis sévère ou choc septique selon les 
critères de Bone (1 ). Les données cliniques et paracliniques ont été relevées au 
moment de l'épisode. Des courbes de survie uni- et multivariées ont été établies à 
28 jours et à long terme chez ceux qui ont survécus plus de 28 jours, d'après les 
données de questionnaires envoyés aux médecins traitants. 
Résultats : Durant la période de l'étude, 339 patients ont présenté un choc 
septique (169) ou une sepsis sévère (170). La mortalité à 28 jours a été de 33% 
(choc septique: 55%, sepsis sévère: 11.2%, p<l0-5). Les données significativement 
associées à la mortalité à 28 jours dans l'analyse de régression multivariée selon 
Cox ont été le type d'épisode septique (choc septique vs. sepsis sévère, p=0.001), 
le «Acute Physiology Score» du score APACHE II (p=0.02) et le nombre de 
dysfonctions d'organes (plus de trois dysfonctions, p=0.04). 
227 patients ont survécu plus de 28 jours et des données de suivi ont été obtenues 
chez 225. Le suivi moyen après 28 jours a été de 25.1 mois (5700 mois-patients). 
La mortalité globale de ces patients, extrapolée des courbes de Kaplan-Meyer, a 
été de l'ordre de 7% à 1 an et de 15% à 2 ans. Les données significativement 
associées à leur survie à long terme ont été les «chronic health points» du score 
APACHE II (p=0.02), l'âge (p=0.05) et le fait d'avoir subi une opération 
chirurgicale avant l'épisode septique (p=O. 02). 
Conclusion : La mortalité à 28 jours de notre cohorte de patients s'est révélée 
comparable aux chiffres publiés. La survie à long terme des patients ayant survécu 
plus de 28 jours a été satisfaisante. Elle s'est révélée indépendante de la sévérité 
de l'épisode septique, mais dépendait plutôt des conditions de santé sous-jacentes. 
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Introduction 
Severe sepsis and septic shock account for 11 % of admissions into intensive care 
units. Each year, more than 750'000 cases have been estimated to occur in the 
United States and the incidence is projected to increase by 1.5% per year (2). In-
hospital mortality of patients with severe sepsis remains near 30% (2, 3, 4, 5) and 
increases to more than 60% in case of shock, despite advances in the management 
of critically ill patients ( 4, 6, 7). Severe sep sis and septic shock remain the second 
cause of mortality in non-coronary intensive care units (ICU) (3, 8). 
Since sepsis is an acute disease, most studies have used an end-point of 28 days 
for assessing mortality. When the present study was undertaken, the long-term 
survival of patients surviving the episode of severe sepsis or septic shock was 
largely unknown. The knowledge of long term survival was lacking to assess the 
cost-benefit of investigational therapeutic interventions. Since then, a few studies 
have followed patients beyond 28 days (4, 5, 7, 9). 
This study had two main purposes: first, to compare 28 days mortality rates 
observed in our hospital with rates from similar cases published in the literature; 
second, to assess the long term survival of patients who survived more than 28 
days. A secondary purpose was to identify clinical or laboratory predictors for 28 
day survival and long term survival. 
The first part of the study was a retrospective analysis during a three-year period 
of all patients of the adult medical and surgical intensive care units (ICU) of the 
CHUV (Centre Hospitalier Universitaire Vaudois) in Lausanne, Switzerland. 
Patients who met the criteria of severe sepsis or septic shock (1) during their stay 
in the ICU were enrolled in our study. Data was collected from their medical files 
and mortality was analyzed. The second part of the study was an assessment of 
duration and quality of survival by mean of a questionnaire sent to the physicians 
in charge of the patients after discharge from the hospital or by mean of a 
telephone call to the patients themselves when no answer from the physician could 
be obtained. 
Material and methods 
Patient selection 
The entry registries of the ICU units and the VESKA diagnostic code listings of 
all patients admitted to the adult medical and surgical intensive care units (ICU) of 
the CHUV between 1.1.1990 and 31.12 .1992 were both reviewed. The entry 
registries are books where the main diagnoses leading to ICU admission are 
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reported manually for each patient. The VESKA coding system was used at the 
time of the study in Swiss hospitals for coding medical diagnosis and procedures 
for statistic purposes before the implementation of the ICD coding system (10). 
The medical files of all patients with any diagnosis suggesting sepsis or infection 
were then carefully screened for episodes of severe sepsis or septic shock using 
the criteria defined by Bone RC et al (1). 
Definitions 
Sepsis is defined as the systemic response to infection manifested by two or more 
of the following conditions as a result of infection: temperature >38°C or <36°C, 
heart rate >90/min, respiratory rate >20/min or PaC02 <32tntnHg, WBC > 12'000 
or <4000 cells/tntn3 or > 10% immature (band) forms. 
Severe sepsis is defined as sepsis associated with organ dysfunction, 
hypoperfusion, or hypotension. Hypoperfusion and perfusion abnormalities may 
include, but are not limited to lactic acidosis, oliguria, or an acute alteration in 
mental status. 
Septic shock is defined as sepsis with hypotension, despite adequate fluid 
resuscitation, along with the presence of perfusion abnormalities that may include, 
but are not limited to lactic acidosis, oliguria, or an acute alteration in mental 
status. Hypotension is a systolic BP of <90 tntnHg or a reduction of >40 tntnHg 
from baseline in the absence of other causes for hypotension. Patients on inotropic 
or vasopressor agents may not be hypotensive at the time of perfusion 
abnormali ties. 
Organ dysfunctions and perfusion abnormalities are defined as follows: lung 
dysfunction: respiratory rate > 20 or PaC02 < 32 mm Hg; kidney dysfunction: 
diuresis < 30 ml/h or plasma creatinin > 128 µmol/l; alteration of mental status 
due to sepsis; liver dysfunction: ASAT > 120 U/l or total plasma bilirubin > 25 
tntnol/l; lactic acidosis: lactate> 2.44 mmol/l; activation of coagulation. 
Sepsis was the reason for admission to the ICU in some patients whereas it 
occurred as a complication during the ICU stay in others. In these latter cases, day 
0 was defined as the first time when the criteria of severe sepsis or septic shock 
were fully met. If severe sepsis preceded for a few hours a full picture of septic 
shock, the patient was classified as septic shock. When more than one episode of 
severe sepsis or septic shock occurred, only the worst was analyzed. 
Data collection 
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The following data were collected at day 0: diagnosis (severe sepsis or septic 
shock), clinical diagnosis of infection, blood culture results, sex, age, body mass 
index (kg/m2), body temperature (°C), white blood cell count (G/l), immature 
white blood cells (%), alveolo-arterial oxygen gradient (mm Hg), Swann-Ganz 
catheter measurements, number of organ failures, APACHE II (11 ), duration of 
follow-up, survival at end of follow-up. 
Data about long-term survival and general health of patients released from the ICU 
were obtained by mean of a questionnaire sent to their physician. The following 
questions were asked: new underlying diseases and disabilities, further 
hospitalizations, date of last follow-up and, when applicable, date and cause of 
death. When there was no answer to the questionnaire, it was sent a second time. 
When the patient was no longer followed by the physician or when the physician 
did not respond to the questionnaire, the patient was contacted by phone. For some 
patients who were hospitalized again, follow-up information was also collected 
from their medical file. On the whole, we were able to obtain follow-up data from 
all but two patients. 
Statistical analysis 
Statistical analysis was performed using SPSS for Windows release 10.1.0. 
Overall survival at 28 days and long term survival (from the 28th day until the end 
of follow-up) were analyzed using Kaplan-Meyer survival analysis. 
For Cox regression survival analysis, clinical or laboratory values were first 
classified into categories when appropriate. 
Variable Cate1:ories 
Type of sep tic episode Septic Severe 
shock sep sis 
Sex female male 
Age [years] <35 35-65 >65 
BMI (body mass index) [kg/m2} <20 20-30 >30 
Body temperature (rectal) {°C} <36.5 36.5-38.0 >38.0 
White blood cell count [G/l] <4 4-12 >12 
Immature white blood cells (bands)[%] <10 >10 
P[A-a}02 (alveolo-arterial oxygen <100 100-200 >200 
gradient) [mm Hg} 
Blood culture results negative Gram+ Gram- other 
Surgery before septic episode no yes 
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Admission to !CU with sepsis no yes 
Nosocomial infection no yes 
Systemic vascular resistance <960 960-1400 >1400 
[(dyn-s)/cm5] 
Number of organ failures 1 2 3 >3 
APACHE II without Glas~ow <10 10-20 >20 
APS without Glasgow <10 10-20 >20 
Chronic health evaluation from 0-2 3-5 
APACHE II 
Chi-square tests were then performed and variables with non significant 
distributions were discarded. The remaining variables were then matched with the 
type of septic episode using bivariate Cox regressions, and the non significant 
variables were also discarded. The remaining variables were submitted to a 
stepwise multivariate Cox regression analysis during which the variables with a p-
value of more than 0.2 were progressively eliminated with the purpose to retain at 
the end only variables with p-values < 0.05. Survival curves were then drawn for 
the variables significantly associated with outcome. 
Results 
Prevalence of sepsis, reason for admission to ICU and acquisition of 
infections 
From 1990 to 1992, 6864 patients were admitted to the ICU (3735 to the surgical 
unit and 3109 to the medical unit). 3 3 9 septic episodes were detected ( 169 with 
severe sepsis and 170 with septic shocks). Therefore the prevalence of septic 
episode, severe sepsis and septic shock in the ICU was: 4.94%, 2.46 and 2.48 % 
respectively. The number of patients with sepsis in surgical and medical ICUs, the 
reasons for admission to ICU and the type of acquisition of infection are 
summarized in table 1. 
Microbiological documentation of sepsis 
Micro-organisms were isolated from blood cultures in 32% of patients. Blood 
cultures isolates are listed in table 2. When blood cultures were classified 
according to the type of isolates (Gram negative bacteria, Gram positive bacteria, 
other micro-organisms or no micro-organism isolated), no correlation was found 
with 28-days- or long-term survival. 
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Sources of follow-up 
The data for the patients' follow-up were drawn from the following sources: 
hospital files in case of new hospitalization, questionnaires sent to physicians or 
outpatients' clinics, or phone call to the managing physicians or the patients 
themselves (table 3). 
Survival Analysis 
1) Kaplan Meyer survival analysis 
1.1) 28-days survival 
Nineteen out of 170 patients with severe sepsis (11.2%) died during the first 28 
days, compared to 93 out of 169 patients with septic shock (55.0 %) (p<l0-5) 
(figure 1). 
1.2) Long term surviva/ (from the 28th day to the end of follow-up) 
Twenty-seven out of 151 patients with severe sepsis who survived the 28th day 
(16.6%) died during the long term follow-up, compared to 15 out of 76 patients 
with septic shock (19.7 %) (N.S.). The overall mortality was about 7% atone year 
and 15% at two years (figure 2). 
2) Cox Regression Survival Analysis 
Univariate and bivariate analysis allowed removing variables which were not 
significantly associated with outcome. The remaining variables were then 
submitted to a stepwise multivariate procedure. 
2.1) 28-days survival 
The following variables were significantly associated with the 28-days mortality: 
type of episode (severe sepsis vs. septic shock, p=0.001), age (<35 y, p=0.02; 35-
65 y, p=0.13; >65 years, p=0.02), acute physiology score (APS) (<10 points, 
p=0.02; 10-20 points, p=0.40; >20 points, p=0.02) and the number of organ 
dysfunctions (1, p=O. l O; 2, p=0.62; 3, p=0.20; >3, p=0.04) (figure 3). 
Both Kaplan Meyer and Cox regression survival analysis showed a very sharp 
initial mortality in patients with septic shock. This sharpness is partly an artifact 
due to the retrospective nature of the study: when the beginning of the septic 
episode was difficult to determine, day 1 was defined as the acme of the episode. 
This was followed by a slightly increased mortality until day 28 in patients with 
septic shock compared to severe sepsis, which was due to the lethal progression of 
acute organ dysfunctions. 
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2.2) Long term surviva/ (survival from the 28th day to the end of follow-up) 
The following variables were significantly associated with long term mortality: the 
chronic health points from the APACHE II score (p=0.02), the age (<35 y, p=0.05; 
35-65 y, p=0.25; >65 y, p=0.02) and surgery before the septic episode (p=0.02) 
(figure 4). The type of episode (severe sepsis vs. septic shock, the strongest 
predictor of 28-days mortality) (figure 4), as well as other markers of sepsis 
severity (APS, number of organ dysfunctions) (curves not shown) were not 
significantly associated with long term outcome. 
Discussion 
Advances in the treatment of severe sepsis and septic shock are needed since 
mortality remains very high despite the best available care (2, 3). When this study 
was undertaken, several new approaches were under investigation, such as anti-
endotoxin antibodies and various drugs or antibodies aimed at regulating the 
inflammatory or coagulation cascades (12, 13, 14, 15, 16, 17). However, the long 
term survival of septic patients was not well known, because most of the available 
studies examined 28-days survival. 
This retrospective study including all patients who suffered from severe sepsis and 
septic shock in the surgical and medical ICU of the CHUV in Lausanne from 1990 
to 1992 was undertaken to improve knowledge on long term survival. W e first 
assessed the 28-days survival in our patients and found that it was similar to 
published data. Thus, our cohort of patients was a fair representation of the 
population of septic patients in other studies. We then analyzed the long term 
survival of the patients who were alive after 28 days. Follow up information was 
obtained for all but only two patients. Mean follow-up was 25.1 month (5700 
patient-months). We found that the overall mortality inferred from the Kaplan-
Meyer curve was about 7% at one year and about 15% at two years. The long term 
mortality was significantly associated with the age, the chronic health points from 
the APACHE II score and whether surgery had been performed before the septic 
episodes. The severity of the septic episodes was not a predictor of the long term 
mortality, in sharp contrast with the 28-days mortality. These findings allow us to 
conclude that the overall survival of septic patients is mainly related to their 
underlying conditions, and not to the septic episode itself. 
Other studies of long term survival after sepsis have been published more recently. 
Perl et al. have examined long term survival of 103 patients in the University of 
Iowa Hospitals and Clinics, meeting the consensus criteria of organ failure and 
sep sis (1 ), and who were enrolled into a double-blind placebo controlled efficacy 
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trial of monoclonal antiendotoxin antibody from 1986 to 1990. Follow up was 877 
days. The study was limited to patients with suspected gram negative sepsis and 
has been published in 1995 (7). The strongest predictor of long term survival in 
the study model was the severity of underlying diseases as classified by McCabe 
and Jackson. The authors found that physical dysfunction and more poorly 
perceived general health occurred commonly after sepsis. 30 day mortality was 32 
% and mortality at one year 4 7 %, which means that 15% of patients surviving 
after 30 days died during the 11 following months. The long term impact of the 
type of episode (severe sepsis vs. septic shock) on the 28-days survivors was not 
analyzed. 
Quartin et al. examined survival of 1505 patients with sepsis enrolled in a Study of 
corticosteroids of whom 45% had septic shock, 15% severe sepsis and 40% 
uncomplicated sepsis. The study, published in 1997, was conducted from 1983 to 
1986 in Veteran Affairs Medical Centers in the United States. Survival was 
followed during 8 years and compared to a control population consisting of all non 
psychiatrie and non infected patients hospitalized in the participating hospitals 
during the year 1985 (18). The authors found that the septic population was at 
significant risk of dying of nonseptic causes and that their overall mortality was 
higher than controls for the first 5 years. Mortality was 50% at 30 days and 23% 
of the 30-days survivors died during the 11 following months. This is clearly 
higher than our findings, reflecting probably the presence of higher age and 
comorbidities in Veterans' Affair facilities. They mentioned that the overall one 
year mortality was 71 % for severe sepsis and 80% for septic shock, but they did 
not report the one year mortality in the 28-days survivors. 
W eyecker et al. conducted a large scale retrospective cohort study including more 
than 16'000 patients with ICD-9-CM codes suggestive of infection and organ 
dysfunction recruited from a U.S. health insurance claims database covering 
approximately three million members during a period of 10 years from 1991 to 
2000. Follow up was 5 years. The study has been published in 2003 ( 4). The 
mortality was 21.2% during hospitalization, 51.4% at 1 year, 64.8 % at 3 years and 
74.2% at 5 years. The long term mortality was thus higher than our findings, 
which is probably explained by differences between both populations. Indeed, the 
criteria for admission into their study were not based on the Bone' s definition for 
sepsis. In addition, 81 % of their patients were older than 65 years, whereas the 
mean age in our study was 54.7 years. 
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Angus et al. examined long term survival of 1690 patients with severe sepsis 
enrolled in the international multiple-center trial of drotrecogin alpha 
(recombinant activated Protein C) vs. placebo (PROWESS). Patients were 
enrolled from 1998 to 2000 and followed for a maximum of 3.6 years. The results 
were published in 2004 (9). The population of patients in this study was probably 
closely related to our own study population, since similar criteria were used for 
sepsis definition (19), patients were treated in intensive care units and ages were 
similar (mean ages were 50.4 years in placebo and 54.2 years in drotrecogin alpha 
vs. 54.7 years in our population). However, the patients' septic episodes were not 
classified into severe sepsis or septic shock. While early survival benefit was 
observed in subjects with APACHE II scores >25 receiving drotrecogin alpha, this 
advantage lost statistical significance after hospital discharge. Overall survival 
rates for drotrecogin alpha vs. placebo were 66.1 % vs. 62.4% at 3 months, 62.2% 
vs. 60.3% at 6 months, 58.9% vs. 57.2% at 1 year, and 52.6% vs. 49.3% at 2 Yi 
years. Thus long term mortality was comparable to our findings. 
Twenty years after collecting our data, the overall mortality of severe sepsis and 
septic shock remains unfortunately virtually unchanged. Innovative approaches are 
still elusive. Our data, as well as others, suggested that patients after septic 
episodes had acceptable long term survival dictated mainly by their underlying 
conditions. In particular, our study is the only one which clearly demonstrated that 
the severity of the septic episode (severe sepsis vs. septic shock) was not related to 
long term survival in 28-days survivors. These findings justify the allocation of 
substantial resources to research on the treatment of these conditions, given their 
high incidence in intensive care units, their high immediate mortality, and the 
good prognosis of survivors. 
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Table 1. Number of patients in surgical and medical ICUs, reasons for admission 
to ICU and type of acquisition of infection. 
Ali Severe Sepsis Septic Shock 
Type of/CU 
Surgical unit 185 88 97 
Medical unit 154 81 73 
Total 339 169 170 
Reason for admission to /CU 
Sepsis 223 97 126 
Acute disease other than sepsis 70 42 28 
Postoperative management 25 18 7 
Trauma 12 10 2 
Late postoperative 7 2 5 
complication 
Other 2 2 
Acquisition of infection 
Community-acquired 179 72 107 
Ho spi tal-acquired 160 98 62 
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Table 2. Results of blood cultures. 
Ali episodes Severe sepsis Septic shock 
Ali patients 339 169 170 
Patients with positive blood 109 (32) 43 (25) 66 (39) 
cultures (%) 
Number of micro-organisms 138 49 89 
isolated 
Gram positive 
Streptococcus pneumoniae 21 7 14 
Staphylococcus aureus 17 9 8 
Other aerobic 16 8 8 
streptococcus 
Staphylococcus 13 7 6 
epidermidis 
Streptococcus pyogenes 4 1 3 
Other gram positive 3 3 
Total Gram positive 74 (53.6) 32 (65.3) 42 (47.2) 
(%) 
Gram ne1:ative 
Escherichia coli 26 6 20 
Enterobacter sp 6 1 5 
Klebsiella sp 5 2 3 
Pseudomonas aeruRinosa 3 1 2 
Other gram negative 11 2 9 
Total Gram negative 51 (36.9) 12 (24.5) 39 (43.8) 
(%) 
Anaerobes (n, %) 
Bacteroides fragilis 3 3 
Other anaerobes 2 1 1 
Total anaerobes (%) 5 (3.6) 1 (2.0) 4 (4.5) 
Funl(i 
Candida sp 7 4 3 
Other fungi 1 1 
Total fungi (%) 8 (5.8) 4 (8.2) 4 (4.5) 
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Table 3. Source of data for the 227 patients surviving more than 28 days . 
Source of follow-up Family . Out-patients' Patient Total 
doctor clinic himse(f 
Death during hospital stay 11 
New hospitalization 11 
Questionnaire 125 16 141 
Phone call 21 8 33 62 
Lost for follow-up 2 
Total 227 
Figure 1. Kaplan-Meyer 28-days survival analysis of patients with severe sepsis 
or septic shock. 
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Figure 2. Kaplan-Meyer long term survival analysis of patients with severe sepsis 
or septic shock who survived the first 28 days 
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Figure 3. 28-days Cox regression survival analysis. 
Figure 3.1. Comparison of patients with severe sepsis or septic shock 
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Figure 3.2. Comparison of patients <35, 35-65 or >65 years old 
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Figure 3.3. Comparison of patients with acute physiology score <10, 10-20 or >20 
points 
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Figure 3.4. Comparison of patients with 1, 2, 3 or >3 organ failures 
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Figure 4. Long term Cox regression survival analysis of the patients who survived 
more than 28 days. 
Figure 4.1. Comparison of patients with severe sepsis or septic shock 
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Figure 4.2. Comparison of patients with 0-2 or 3-5 chronic health points from the 
APACHE II score 
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CH_ G2 = chronic health points from APACHE II 
Figure 4.3. Comparison of patients <35, 35-65 or >65 years old 
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Figure 4.4. Comparison of patients with or without surgery 
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POSTOP = postoperative status 
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